Insight Molecular Diagnostics (IMDX) closed at $1.97 on November 20, 2026, up 18.7% from the previous close, on volume of 1,154,565 shares (30-day average 231,904).
Data as of November 20, 2026.
20-Nov-2026
iMDx Expands GraftAssure Utilization as First Patient Samples Arrive for GALACTIC Registry Study
Globe Newswire (Fri, 20-Nov 8:00 AM ET)
Insight Molecular Diagnostics Announces Public Offering of Shares
TipRanks (Wed, 18-Nov 5:37 PM ET)
Insight Molecular Diagnostics Earnings Call Signals Launch Momentum
TipRanks (Tue, 17-Nov 7:14 PM ET)
Insight Molecular Diagnostics Announces Pricing of $15 Million Public Offering
Globe Newswire (Tue, 17-Nov 8:00 AM ET)
IMDx Reports Third Quarter 2026 Results and Provides Corporate Update
Globe Newswire (Mon, 16-Nov 4:56 PM ET)
Insight Molecular Diagnostics Announces Proposed Public Offering
Globe Newswire (Mon, 16-Nov 4:10 PM ET)
iMDx to Release Third Quarter Results on November 16, 2026
Globe Newswire (Thu, 5-Nov 7:00 AM ET)
iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx Launch
Globe Newswire (Wed, 14-Oct 8:00 AM ET)
Market Chameleon (Mon, 12-Oct 7:38 AM ET)
Globe Newswire (Mon, 12-Oct 8:00 AM ET)
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
Insight Molecular Diagnostics trades on the NASDAQ stock market under the symbol IMDX.
As of November 20, 2026, IMDX stock price climbed to $1.97 with 1,154,565 million shares trading.
IMDX has a beta of 1.81, meaning it tends to be more sensitive to market movements. IMDX has a correlation of 0.13 to the broad based SPY ETF.
IMDX has a market cap of $80.88 million. This is considered a Micro Cap stock.
Last quarter Insight Molecular Diagnostics reported $559,000 in Revenue and -$.10 earnings per share. This beat revenue expectation by $314,720 and exceeded earnings estimates by $.12.
The top ETF exchange traded funds that IMDX belongs to (by Net Assets): VTI, VXF, IWC.
IMDX has underperformed the market in the last year with a price return of -67.5% while the SPY ETF gained +6.9%. IMDX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -54.2% and -20.9%, respectively, while the SPY returned -9.3% and -6.2%, respectively.
IMDX support price is $1.51 and resistance is $1.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMDX shares will trade within this expected range on the day.